Literature DB >> 31665232

Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.

Jun Yoshino1,2, Yoshimitsu Akiyama1, Shu Shimada1, Toshiro Ogura2, Kosuke Ogawa2, Hiroaki Ono2, Yusuke Mitsunori2, Daisuke Ban2, Atsushi Kudo2, Shoji Yamaoka3, Minoru Tanabe2, Shinji Tanaka1,2.   

Abstract

Genomic analyses have recently discovered the malignant subtype of human intrahepatic cholangiocarcinoma (ICC) characterized by frequent mutations of chromatin remodeling gene ARID1A; however, the biological and molecular functions still remain obscure. We here examined the clinical and biological significances of ARID1A deficiency in human ICC. Immunohistochemical analysis demonstrated that the loss of ARID1A was an independent prognostic factor for overall survival of ICC patients (P = 0.023). We established ARID1A-knockout (KO) cells by using the CRISPR/Cas9 system from two human cholangiocarcinoma cell lines. ARID1A-KO cells exhibited significantly enhanced migration, invasion, and sphere formation activity. Microarray analysis revealed that ALDH1A1, a stemness gene, was the most significantly elevated genes in ARID1A-KO cells. In addition, ALDH enzymatic activity as a hallmark of cancer stem cells was markedly high in the KO cells. ARID1A and histone deacetylase 1 were directly recruited to the ALDH1A1 promoter region in cholangiocarcinoma cells with undetectable ALDH1A1 expression by chromatin immunoprecipitation assay. The histone H3K27 acetylation level at the ALDH1A1 promoter region was increased in cells when ARID1A was disrupted (P < 0.01). Clinically, inverse correlation between ARID1A and ALDH1A1 expression was also identified in primary ICC (P = 0.018), and ARID1A-negative and ALDH1A1-positve ICCs showed worse prognosis than only ARID1A-negative cases (P = 0.002). In conclusion, ARID1A may function as a tumor suppressor in ICC through transcriptional downregulation of ALDH1A1 expression with decreasing histone H3K27 acetylation. Our studies provide the basis for the development of new epigenetic approaches to ARID1A-negative ICC. Immunohistochemical loss of ARID1A is an independent prognostic factor in intrahepatic cholangiocarcinoma patients. ARID1A recruits HDAC1 to the promoter region of ALDH1A1, a stemness gene, and epigenetically suppresses ALDH1A1 expression with decreasing histone H3K27 acetylation in cholangiocarcinoma cells.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31665232     DOI: 10.1093/carcin/bgz179

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

Review 1.  Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.

Authors:  Garrett M Dancik; Ioannis F Voutsas; Spiros Vlahopoulos
Journal:  Mol Biol Rep       Date:  2022-01-14       Impact factor: 2.316

Review 2.  ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism.

Authors:  Hanxun Yue; Zenan Hu; Rui Hu; Zeying Guo; Ya Zheng; Yuping Wang; Yongning Zhou
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

3.  Valproic Acid Induces Autism-Like Synaptic and Behavioral Deficits by Disrupting Histone Acetylation of Prefrontal Cortex ALDH1A1 in Rats.

Authors:  Huan Liu; Mei Tan; Boli Cheng; Si Wang; Lu Xiao; Jiang Zhu; Qionghui Wu; Xi Lai; Qian Zhang; Jie Chen; Tingyu Li
Journal:  Front Neurosci       Date:  2021-04-28       Impact factor: 4.677

Review 4.  The Current State of Chromatin Immunoprecipitation (ChIP) from FFPE Tissues.

Authors:  Stefano Amatori; Mirco Fanelli
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

Review 5.  CRISPR/Cas9 in Gastrointestinal Malignancies.

Authors:  André Jefremow; Markus F Neurath; Maximilian J Waldner
Journal:  Front Cell Dev Biol       Date:  2021-11-29

6.  Expression Signature of the AT-Rich Interactive Domain Gene Family Identified in Digestive Cancer.

Authors:  Yongqu Lu; Zhenzhen Liu; Wendong Wang; Xin Chen; Xin Zhou; Wei Fu
Journal:  Front Med (Lausanne)       Date:  2022-01-20

7.  ARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in Patients With Gallbladder Cancer.

Authors:  Lingxi Nan; Changcheng Wang; Jie Wang; Shulong Zhang; Xiaobo Bo; Yueqi Wang; Houbao Liu
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

Review 8.  Roles of ARID1A variations in colorectal cancer: a collaborative review.

Authors:  Shankun Zhao; Weizhou Wu; Zufu Jiang; Fuqin Tang; Lingzhi Ding; Weifang Xu; Libin Ruan
Journal:  Mol Med       Date:  2022-04-14       Impact factor: 6.354

Review 9.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

10.  Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients.

Authors:  Giuliana Cavalloni; Caterina Peraldo-Neia; Annamaria Massa; Carlo Bergamini; Alessandro Trentini; Giovanni De Rosa; Lorenzo Daniele; Fabiola Ciccosanti; Carlo Cervellati; Francesco Leone; Massimo Aglietta
Journal:  BMC Cancer       Date:  2021-07-28       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.